Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.